Last reviewed · How we verify
NCT06560346: EARLY-FA
Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia
trial testing Geneticlly confirmed disease causing FXN mutatuion in Friedreich Ataxia. Withdrawn.
1 December 2028
Quick facts
| Lead sponsor | Friedreich's Ataxia Research Alliance |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 May 2025 |
| Primary completion | 1 December 2028 |
| Estimated completion | 1 December 2028 |
| Sites | 7 locations across Italy, Germany, Canada, Australia, United States |
Drugs / interventions tested
- Geneticlly confirmed disease causing FXN mutatuion
- Healthy Control
Conditions studied
- Friedreich Ataxia — all drugs for Friedreich Ataxia →
- Rare Diseases — all drugs for Rare Diseases →
Sponsor
Friedreich's Ataxia Research Alliance
Who can join
Adults 4 to 21, any sex, with Friedreich Ataxia or Rare Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multicenter, prospective, observational natural history and outcome measure study of children and young adults with Friedreich ataxia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06560346
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Friedreich Ataxia
Currently open trials in the same condition.
- NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
- NCT07508631 — Friedreich Ataxia Nerve Ultrasund · recruiting
- NCT06953583 — A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich' · Phase 3 · recruiting
- NCT06623890 — A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who · recruiting
- NCT06054893 — A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participa · Phase 1 · recruiting
Other Friedreich's Ataxia Research Alliance trials
Trials by the same sponsor.
- NCT06016946 — Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study · recruiting
- NCT03090789 — FA Clinical Outcome Measures · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06560346 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Friedreich's Ataxia Research Alliance
- Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06560346.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing